Carryover vaccine strain does not confer protection to cell recipients against lethal challenge.

(A) Weight loss (left) and survival (right) of Rag2^-/- Il2rg^-/- mice that received different numbers of splenocytes from week 2-TAS2010 infected mice, and the recipients were challenged with 200CFU SL1344 24h after adoptive transfer. (B) Weight loss (left) or survival (right) of Rag2^-/- Il2rg^-/- mice that received i.v. 5×10⁷ splenocytes from either week 2-TAS2010 infected B6, or uninfected B6, or did not receive cells; control that were adoptively transferred ~200 CFU TAS2010 along with splenocytes (*) or injected with 200CFU TAS2010 i.v. at the time of transfer. 24h post-transfer recipients were challenged with SL1344 or left unchallenged. Data is representative of (A,B) 2 pooled independent experiments, with (A) 10 (B) 7–10 animals per group. Statistical analysis, log-rank (Mantel-Cox). **p<0.01, ***p<0.005.

(TIF)